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_________________________________________________________________________________________________________	
Abstract		
	
OBJECTIVES:	 Prosthetic	 valve	 thrombosis	 during	 pregnancy	 is	 associated	 with	 serious	 maternal	
complications	 and	 considerable	 fetal	 loss.	We	 report	 and	 analyze	 the	outcome	of	 surgery	 in	 critically	 ill	
patients	referred	to	our	tertiary	center	between	January	2009	and	January	2015.		
METHODS:	 Twenty-eight	pregnant	patients	with	median	age	of	28	years	 (range:	20-40	years)	presented	
with	 thrombosed	 bileaflet	 mechanical	 mitral	 valve	 prostheses,	 48	 (15-192)	 months	 after	 implantation.	
Twenty-two	patients	 (78.6%)	were	on	 fixed	dose	 LMWH	 (1	mg/kg	 twice	daily)	 and	 six	 patients	were	on	
warfarin,	with	an	INR	<1.4	in	four	cases	(66.6%).		Patients	were	reported	as	being	critically	ill	since	4	(1-12)	
days	and	presented	in	NYHA	class	IV	(III-IV),	with	median	gestational	age	(GA)	of	31	(8-40)	weeks.	We	had	
six	cases	of	confirmed	stillbirth	(21.4%)	on	admission.	The	remaining	were	14	patients	presenting	with	GA	
>28	weeks	(Group	1)	and	8	patients	with	GA	<28	weeks	(Group	2).	Delivery	was	planned	before	bypass	in	
Group	 1.	Measures	 of	 fetal	 protection	 during	 surgery	 included:	 >2.7	 L/m2/min	 high	 flow	normothermic	
bypass	maintaining	mean	perfusion	pressure	>	70mm	Hg	and	keeping	hematocrit	>28%.	
RESULTS:	 All	 mitral	 prostheses	 were	 emergency	 replaced	 with	 same-sized	 mechanical	 valves.	 Median	
aortic	 cross	 clamp	 and	 bypass	 times	were	 57	 (34-106)	 and	 93	 (48-140)	minutes.	We	 had	 two	maternal	
mortalities	 (7.1%)	 and	 one	 preoperative	 regressive	 stroke	 (3.6%).	 Thirteen	 fetuses	 (59.1%)	 were	
successfully	delivered	before	surgery	(92.8%	of	Group	1)	and	nine	were	submitted	to	bypass:	one	rapidly	
deteriorating	Group	 1	 patient	 and	 all	 eight	 patients	 in	Group	 2.	Only	 three	 fetuses	 (GA	 =10,	 21	 and	 31	
weeks)	survived	bypass	(33.3%)	and	were	delivered	at	term.	Outcome	of	the	22	live	fetuses	on	admission	
was:	 14	 live	 births	 in	Group	1	 (100%;	 9	 healthy	babies	 and	5	 prematures)	 versus	 two	 in	Group	2	 (25%;	
P<0.001),	with	a	total	fetal	loss	of	27.3%.		
CONCLUSION:	Maternal	outcomes	are	comparable	to	those	of	non-pregnant	subjects.	Unless	the	fetus	is	
delivered	before	bypass,	the	heavy	fetal	loss,	especially	in	patients	presenting	with	GA	<28	weeks,	calls	for	
applying	more	safety	bypass	measures.	Controlled	 randomized	 trials	are	equally	needed	 to	evaluate	 the	
alternative	fibrinolytic	therapy.		
Keywords:	mitral	valve,	heart	valve	prosthesis,	 thrombosis,	pregnancy,	gestational	age,	cardiopulmonary	
bypass.	
_______________________________________________________________________________________	
INTRODUCTION:	Prosthetic	 valve	 thrombosis	 (PVT)	 is	 a	 major	complication	of	mechanical	valve	replacement,	which	 risk	 is	 expected	 to	 increase	 during	
pregnancy.	 Besides	 being	 a	 hypercoagulable	state,	 expecting	 mothers	 often	 lose	 the	privilege	 of	 the	 effective	 thromboprophylaxis	offered	 by	 oral	 anticoagulants	 when	 they	 are	shifted	 to	 Heparin,	 in	 order	 to	 improve	 fetal	
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outcomes	 and	 to	 avoid	 the	 risk	 of	 warfarin	induced	 embryopathy	 [1-3].	 Two	 large	systematic	 reviews	 involving	 2577	 pregnant	patients	 with	 mechanical	 valve	 prostheses	(MVP)	have	clearly	shown	that	the	incidence	of	prosthetic	 valve	 thrombosis	 during	 pregnancy	(PVTP)	 in	 patients	 still	 following	 oral	anticoagulants	 (1.2%-3.9%)	 was	 tripled	 in	those	shifting	to	Heparin	derivatives	during	the	first	 trimester	 (5.3-9.2%)	 and	 finally	 reached	as	much	as	10.2%-33.3%	in	patients	continuing	parenteral	anticoagulation	till	term	[4,5].	
Patients	with	PVTP	are	usually	referred	to	
our	tertiary	center	in	NYHA	class	III-IV	and	after	a	
considerable	 time	 delay	 from	 the	 onset	 of	
alarming	 symptoms.	 Following	 the	 current	
guidelines	 [1-3],	 we	 managed	 those	 critically	 ill	
patients	 surgically	 and	 herein	 we	 report	 and	
analyze	the	outcomes.		
	
MATERIAL	AND	METHODS	
In	the	period	between	January	2009	and	January	
2015,	 patients	 referred	 to	 the	 department	 of	
cardiothoracic	 surgery	 of	 Ain	 Shams	 	 University	
hospitals	 with	 a	 preliminary	 diagnosis	 of	 PVTP	
represented	 an	 exclusive	 surgical	 emergency.	
After	 reviewing	 their	 surgical	 and	 obstetrical	
history,	 patients	 were	 investigated	 for	 recent	
shortness	 of	 breath,	 palpitation,	 muffling	 of	
mechanical	 valve	 clicks,	 symptoms	 suggesting	
thromboembolic	events	or	other	prosthetic	valve	
related	complications.	All	patients	benefited	from	
a	 full	 clinical	 as	 well	 as	 transthoracic	
echocardiographic	 examination	 and,	 in	 case	 of	
suspicion,	 they	 were	 further	 subjected	 to	
transesophageal	 echo	 (TEE)	 or	 fluoroscopy	 for	
better	 assessment	 of	 leaflet	 mobility.	 An	
obstetrician	checked	fetal	viability	and	confirmed	
gestational	 age	 (GA).	 All	 examinations	 and	
investigations	were	 conducted	on	 an	emergency	
basis.	 Once	 PVTP	 was	 confirmed,	 mothers	 were	
admitted	 to	 the	 intensive	 care	unit	 (ICU)	 for	 full	
hemodynamic	monitoring	 and	 support,	 while	 all	
measures	were	taken	for	emergency	surgery.	This	
report	 only	 concerns	 critically	 ill	 pregnant	
patients	 presenting	 with	 PVTP	 and	 fulfilling	 the	
following	 criteria:	 (i)	 Patient	 presenting	 with	
NYHA	class	III-IV	due	to	PVTP	and	not	due	to	any	
other	 comorbidity.	 (ii)	 Echocardiographic	
examination	showing	that	the	thrombus	is	either	
obstructive	 or	 otherwise	 large	 (>1	 cm	 in	
diameter)	 or	 mobile	 with	 recent	 systemic	
embolization.		
In	 the	 cardiac	 operation	 room,	 patients	
with	 GA	 >28	 weeks	 were	 scheduled	 for	 an	
emergency	Cesarean	section,	unless	spontaneous	
delivery	 has	 already	 occurred.	 The	 neonate	 was	
transferred	 to	 the	 neonatal	 ICU.	 Mother	 was	
infused	 with	 Oxytocin	 for	 two-hours	 and	 the	
uterus	 was	 packed	 before	 commencing	
emergency	valve	surgery.	Patients	were	routinely	
positioned	 supine,	 except	 still	 gravid	 mothers	
with	 GA	 >	 20	 weeks	 who	 were	 positioned	 on	 a	
left	 lateral	 decubitus	 to	 reduce	 aorto-caval	
compression	 by	 the	 enlarged	 uterus.	 Our	
operative	 technique	 included	 femoral	 artery	
exposure	 before	 reopening	 sternotomy	 with	 an	
oscillating	sternal	saw.	Adhesions	were	dissected	
first.	 Patients	 were	 fully	 heparinized	 and	 non-
pulsatile	 cardiopulmonary	 bypass	 (CPB)	 was	
instituted.	 Gravid	 patients	 were	 kept	
normothermic	 with	 a	 flow	 rate	 >	 2.7	 L/m2/min	
and	 a	mean	perfusion	pressure	 >	 70mm	Hg	was	
maintained	 by	 increasing	 flow	 and	 avoiding	 the	
use	 of	 vasoconstrictors	 as	 much	 as	 possible.	
Other	 patients	 benefited	 from	 routine	 mild	
hypothermic	 CPB,	 with	 a	 flow	 rate	 of	 2.4	
L/m2/min.	 Excessive	 hemodilution	 was	 avoided	
and	 hematocrit	 was	 kept	 above	 28%	 by	 adding	
packed	red	blood	cells	when	needed.	Myocardial	
protection	 was	 achieved	 with	 antegrade	 cold	
blood	cardioplegia,	given	 intermittently	every	30	
minutes.	 There	 were	 no	 attempts	 for	 simple	
thrombectomy	 and	 all	 malfunctioning	 valves	
were	 replaced	 by	 the	 same	 size	 mechanical	
prosthesis.	 In	 patients	 benefiting	 from	 Cesarean	
section	before	bypass,	the	abdominal	wound	was	
then	inspected	and	closed	after	chest	hemostasis	
was	established.	
Statistical	 analysis:	 Data	 were	 presented	
as	 numbers	 (%)	 or	 median	 (range).	 The	
distribution	 of	 fetal	 mortality	 between	 patients	
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presenting	 before	 GA	 of	 28	 weeks	 and	 those	
presenting	afterwards	was	analyzed	by	a	bilateral	
Fisher’s	exact	test,	with	the	P	value	of	0.05	as	the	
limit	of	statistical	significance.		
	
RESULTS	
	
In	the	period	between	January	2009	and	January	
2015,	28	patients	fulfilled	the	inclusion	criteria	for	
this	 report.	 The	 common	 main	 presenting	
symptom	 was	 progressive	 shortness	 of	 breath	
over	 the	 last	 few	 days	 (median	 4;	 range	 1-12	
days).	 It	 was	 associated	 with	 palpitation	 in	 18	
cases	(64.3%),	by	the	patient	noticing	muffling	or	
absence	 of	 valve	 clicks	 in	 7	 cases	 (25%)	 and	 a	
cerebrovascular	 stroke	 with	 left	 sided	
hemiparesis	 in	 one	 case	 (3.6%).	 Table	 1	 shows	
patients	 and	 fetus	 main	 demographics	 and	
outcomes.	 Median	 maternal	 age	 was	 28	 years	
(range:	 20-40	 years).	 Median	 GA	 was	 31	 weeks	
(range:	8-40	weeks):	18	patients	were	 in	GA	>28	
weeks	 and	 10	 patients	 in	 GA	 <28	 weeks.	 The	
majority	of	patients	were	in	NYHA	class	IV	(range:	
III-IV)	 and	 13	 cases	 (46.4%)	 were	 in	 atrial	
fibrillation	 (AF)	 on	 admission.	 Twenty-two	
patients	 (78.6%)	 were	 following	 unadjusted	
1mg/kg	LMWH,	given	twice	daily	and	six	patients	
(21.4%)	 remained	 on	 warfarin	 throughout	
pregnancy,	targeting	an	INR	between	2.5	and	3.5.		
Four	 out	 of	 the	 latter	 (66.6%)	 were	 neglecting	
regular	 prothrombin	 time	 check-up	 and	 their	
median	 international	 normalized	 ratio	 (INR)	was	
1.2	 (1.1	 –	 1.38).	 The	 other	 two	 patients	 had	
managed	 to	 keep	 their	 INR	 within	 the	 target	
range.		
As	 shown	 in	 Table	 1,	 the	 malfunctioning	
mitral	 valve	 prostheses	 were:	 12	 Carbomedics	
valves	 (42.9%),	 10	 St.	 Jude	 Medical	 (35.7%),	 5	
Sorin	bileaflet	(17.9%)	and	one	On-X	valve	(3.6%).	
Median	valve	size	was	27mm	(range:	25-31	mm)	
and	 median	 duration	 of	 implantation	 was	 48	
months	(range:	15–192	months).	In	addition,	two	
patients	 (7.1%:	 Patients	 number	 20	 and	 25)	 had	
the	same	type	aortic	valve	prosthesis	and	7	cases	
(25%)	 had	 previously	 benefited	 from	 DeVega	
tricuspid	valve	annuloplasty.	Diagnosis	was	made	
by	 transthoracic	 echocardiography	 that	 needed	
further	 confirmation	 by	 TEE	 in	 4	 cases	 (14.3%)	
and	 by	 fluoroscopy	 in	 another	 2	 cases	 (7.1%).	
Median	 mitral	 valve	 area	 was	 1cm	 (range:	 0.9-
1.5cm)	 and	 median	 transprosthetic	 gradient	
16mm	 Hg	 (11-28mm	 Hg).	 The	 thrombus	 was	
shown	 to	be	obstructive	 in	 all	 cases,	 except	one	
patient	 who	 had	 an	 embolising	 highly	 mobile	
thrombus	 (3.6%).	 Median	 left	 atrial	 size	 was	
54.5mm	(range:	47-65mm)	and	median	EF%	was	
45	 (range:	 35-55).	 The	 two	 aortic	 valve	
prostheses	 were	 properly	 functioning	 and	 12	
patients	 (42.9%)	 had	 moderate	 to	 severe	
tricuspid	valve	regurgitation.	
Maternal	 outcome:	 All	 thrombosed	
prostheses	 were	 replaced	 with	 the	 same	 size	
mechanical	 prosthesis:	 12	 Carbomedics	 valves	
(42.9%),	 9	 On-X	 valves	 (32.1%)	 and	 7	 St.	 Jude	
Medical	 prostheses	 (25%).	 In	 addition,	 12	
patients	(42.9%)	benefited	from	DeVega	tricuspid	
valve	repair.	Median	aortic	cross	clamp	time	and	
bypass	 times	 were	 57	 minutes	 (range:	 34-106	
minutes)	 and	 93	 minutes	 (range:	 48-140	
minutes).	 We	 had	 two	 maternal	 mortalities	
(7.1%)	and	one	patient	already	presenting	with	a	
cerebrovascular	 stroke	 was	 discharged	 with	
regressive	 left-sided	 hemiplegia	 (3.6%).	 Both	
mortalities	 were	 initially	 following	 unadjusted	
fixed	dose	LMWH,	presented	before	28	weeks	of	
gestation	 and	 were	 due	 to	 multi	 organ	 failure	
after	 prolonged	 bypass	 in	 one	 case	 (patient	 21)	
and	 postoperative	 cerebral	 hemorrhage	 in	 the	
other	 case	 (patient	 25	 in	 Table	 1).	 In	 total,	
median	 amount	 of	 blood	 loss	 was	 600	ml	 (100-
800	 ml)	 and	 no	 cases	 were	 re	 explored	 for	
bleeding.	 Median	 durations	 of	 mechanical	
ventilation,	 positive	 inotropic	 support,	 ICU	 and	
total	hospital	stays	were:	12	hours	 (range:	6-144	
hours),	 6	 hours	 (range:	 2-96	 hours),	 two	 days	
(range:	1-12	days)	and	11	days	(range:	8-17	days);	
respectively.	 Twenty-five	 patients	 were	
discharged	in	NYHA	class	I	(96.1%),	with	only	one	
patient	 being	 in	 NYHA	 class	 II	 (Patient	 number	
20).	 Three	 patients	 continued	 their	 pregnancy	
after	bypass	 (patients	number	9,	19	and	20)	and	
were	 placed	 on	 warfarin	 therapy,	 with	 the	 INR	
being	closely	checked	out	weekly.	Follow-up	was	
uneventful	 till	 term,	 with	 the	 delivery	 of	 three	
healthy	babies	by	elective	Cesarean	section.		
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Table	1:	Patients	and	fetal	demographics	and	outcomes	
	
n	 Age	
(yrs)	
GA		 ACR	 NYHA	
Class	
Valve	
type	
Valve	size	
(mm)	
Implantation	
(months)	
ACC	
(min)	
CPB	
(min)	
Fetal		
outcome	
	
A) Patients	presenting	in	GA	>	28	weeks:	
	
	
1	 29	 40	 LMWH	 4	 Sorin	 29	 78	 60	 100	 Healthy(a)	
2		 27	 39	 LMWH	 4	 CM	 29	 24	 60	 123	 Healthy(a)	
3	 21	 38	 LMWH	 3	 SJM	 25	 48	 77	 110	 Healthy(b)	
4	 36	 37	 LMWH	 3	 SJM	 27	 88	 68	 121	 Healthy(b)	
5	 30	 37	 LMWH	 4	 CM	 27	 75	 55	 77	 Healthy(b)	
6	 31	 37	 LMWH	 4	 CM	 27	 48	 66	 90	 Healthy(b)	
7	 20	 37	 LMWH	 4	 SJM	 27	 62	 52	 80	 Healthy(b)	
8	 28	 40	 Warfarin	 4	 Sorin	 27	 46	 34	 127	 Healthy(b)	
9	 24	 31	 Warfarin	 4	 Sorin	 27	 66	 56	 93	 Healthy(b)	
	 	 	 	 	 	 	 	 	 	 	
10		 23	 35	 LMWH	 3	 CM	 29	 59	 50	 106	 Premature	
11		 33	 35	 LMWH	 3	 SJM	 27	 24	 47	 93	 Premature	
12		 40	 31	 LMWH	 3	 CM	 27	 15	 58	 113	 Premature	
13		 26	 30	 LMWH	 4	 CM	 29	 55	 52	 110	 Premature	
14	 28	 30	 LMWH	 4	 SJM	 29	 79	 48	 89	 Premature	
	 	 	 	 	 	 	 	 	 	 	
15	 37	 35	 Warfarin	(d)	 4	 CM	 29	 57	 58	 76	 Still	birth	(e)	
16	 29	 33	 LMWH	 4	 SJM	 27	 63	 37	 66	 Still	birth	(e)	
17	 29	 31	 UFH	 4	 Sorin	 27	 38	 77	 88	 Still	birth	(e)	
18	 20	 30	 Warfarin	(d)	 3	 Sorin	 29	 33	 65	 89	 Still	birth	(e)	
	
B)	Patients	presenting	in	GA	<	28	weeks:	
	
	
19	 26	 21	 LMWH	 3	 CM	 31	 9	 49	 95	 Healthy(c)	
20	 32	 10	 LMWH	 4	 On-X	(f)	 25	 192	 106	 125	 Healthy(c)	
	 	 	 	 	 	 	 	 	 	 	
21(g)		 35	 22	 LMWH	 4	 CM	 27	 108	 45	 127	 Still	birth	(e)	
22	 29	 19	 LMWH	 4	 CM	 29	 18	 67	 120	 Still	birth		(e)	
23		 37	 18	 LMWH	 4	 CM	 29	 22	 60	 117	 Miscarriage	(h)	
24	 23	 12	 LMWH	 3	 SJM	 27	 38	 65	 77	 Miscarriage	(h)	
25	(g)	 23	 10	 LMWH	 3	 CM	(f)	 27	 75	 52	 77	 Miscarriage	(h)	
26	 23	 9	 LMWH	 4	 SJM	 27	 36	 37	 48	 Miscarriage	(h)	
27	 23	 10	 Warfarin	(d)	 3	 SJM	 27	 38	 60	 105	 Miscarriage	(h)	
28	 25	 8	 Warfarin	(d)	 4	 SJM	 27	 25	 49	 60	 Miscarriage	(h)	
	
n=	patient	number,	Cesarean	section,	GA=	gestational	age	in	weeks,	ACR=anticoagulation	regimen,	ACC	=	
aortic	cross	clamp	time,	CPB	=	cardiopulmonary	bypass	time,	LMWH	=	low	molecular	weight	heparin,	UFH	
=	 unfractionated	 heparin,	 CM	 =	 Carbomedics	 valve,	 SJM=	 St.	 Jude	Medical	 valve,	 Sorin=	 Sorin	 bileaflet	
valve,	On-X=	On-X	valve,	IUFD	=	intra	uterine	fetal	death,	(a)=	spontaneous	vaginal	delivery	before	bypass,	
(b)=	 Cesarean	 section	 before	 bypass,	 (c)	 =	 patients	 continued	 pregnancy	 and	 babies	 were	 delivered	 by	
Cesarean	 section	at	 term	 (d)	=	 INR	below	1.4	at	presentation,	 (e)	=	before	bypass,	 	 (f)	 =	additional	well	
functioning	same	type	aortic	valve	prosthesis,	(g)=maternal	mortality,	h	=	post	bypass.	Patient	number:	2,	
4,	10-14,	19	and	21-23	were	included	in	a	previous	report	[17].	
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Figure	1:	Fetal	outcome	flow	chart	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
GA=	gestational	age,	n	=	number,	Group	1=	patients	presenting	with	live	fetus	with	GA	>28	weeks,	Group	
2=	patients	presenting	with	live	fetus	with	GA	<28	weeks.	
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Fetal	outcome	(Figure	1,	Table	1):	Among	
the	 18	 patients	 presenting	with	GA	 >	 28	weeks,	
there	 were	 already	 four	 cases	 of	 stillbirth	 on	
admission	 (22.2%;	 patients	 15-18).	 In	 the	
remaining	 14	 cases	 (Group	 1),	 we	 managed	 to	
perform	 Cesarean	 section	 before	 bypass	 in	 11	
cases	only	(78.6%),	two	patients	had	spontaneous	
vaginal	 delivery	 before	 section	 (14,3%)	 and	 one	
last	patient	developed	cardiac	arrest	 that	 left	no	
time	but	 to	go	on	bypass	before	delivery	 (7.1%).	
This	 31	 weeks’	 baby	 survived	 bypass	 and	 was	
later	on	delivered	by	Cesarean	section	at	full	term	
(Patient	 number	 9).	 Fetal	 outcome	 for	 Group	 1	
patients	 was:	 nine	 full	 term	 healthy	 babies	
(64.3%)	and	5	prematures	(35.7%).		
We	 had	 two	 cases	 of	 miscarriage	 on	
admission	 (20%:	 patients	 21	 and	 22)	 among	 the	
10	 patients	 presenting	 with	 GA	 <28	 weeks.	 The	
remaining	 eight	 cases	 (Group	 2)	 underwent	
emergency	 bypass	 and	 only	 two	 fetuses	 (25%:	
patients	 19	 and	 20)	 survived	 and	 were	 later	 on	
delivered	 by	 Cesarean	 section	 at	 full	 term.	 In	
total,	9	fetuses	(Patient	number	9	in	Group	1	and	
all	 eight	patients	of	Group	2)	were	 submitted	 to	
emergency	 bypass	 and	 only	 3	 survived	 the	
procedure	(33.3%).	Out	of	22	fetuses	with	proven	
viability	before	surgery	(Group	1	and	2),	a	total	of	
six	 fetuses	 were	 lost	 (27.3%),	 all	 belonging	 to	
Group	 2	 (75%;	 P<0.001).	 Overall	 fetal	 loss	 was	
significantly	 higher	 in	 the	10	patients	presenting	
with	GA	<28	weeks,	compared	to	the	18	patients	
presenting	 with	 GA	 >28	 weeks	 (80%	 versus	
22.2%;	P	=	0.005).		
	
DISCUSSION	
Oral	 anticoagulants	 offer	 the	 best	
thromboprophylaxis	 for	 patients	 with	 MVP.	
Pregnant	 patients	 failing	 to	 achieve	 INR	 target	
with	 a	 relatively	 safe	 dose	 of	 warfarin	 not	
exceeding	5	mg/day	 [1]	as	well	 as	 those	wishing	
to	 avoid	oral	 anticoagulant-related	embryopathy	
and	 fetal	 loss	 can	 shift	 to	 heparin	 either	 during	
the	 first	 trimester	 [1,	 3]	 or	 continuously	 until	
term	 [1-3].	 Heparin	 given	 in	 a	 fixed	 dose	
according	to	the	body	weight	has	been	shown	to	
provoke	 the	 highest	 rates	 of	 thromboembolic	
complications	 during	 pregnancy,	 including	 valve	
thrombosis	 [4,	 5]	 and	both:	UFH	or	 LMWH	have	
to	 be	 adequately	 monitored	 and	 adjusted	 to	
ensure	 better	 prophylaxis[6].	 However,	 a	 recent	
prospective	 European	 report	 of	 220	 pregnant	
patients	with	MVP	showed	an	overall	incidence	of	
PVTP	of	4.7%,	half	of	which	occurring	during	the	
first	 trimester,	 while	 switching	 to	 some	 sort	 of	
Heparin	[7].	The	majority	of	our	patients	were	on	
fixed	dose	LMWH	and	two-thirds	of	 the	patients	
who	 were	 still	 following	 oral	 anticoagulants	
during	 pregnancy	 had	 a	 sub	 therapeutic	 INR	 on	
admission.	 Such	 poor	 compliance	 has	 been	
observed	in	as	much	as	93%	of	the	cases	of	PVTP	
reported	 by	 Ozkan	 and	 colleagues	 [8]	 and,	 at	
least	 on	 our	 side,	 it	 was	 due	 to	 poor	
socioeconomic	conditions.		
The	 current	 guidelines	 for	 managing	
patients	 with	 PVTP	 are	 a	 replica	 of	 those	
originally	 designed	 for	 PVT,	 with	 few	
recommendations	 concerning	 fetal	 protection	
during	 and	 early	 after	 bypass	 [1-3,	 9].	 In	 brief,	
hemodynamically	stable	patients	presenting	with	
a	 recent	 onset	 small	 non-obstructive	 thrombus	
can	 benefit	 from	 a	 short	 period	 of	
anticoagulation	 adjustment	 and	 IV	
heparinotherapy	 under	 strict	 Doppler	
echocardiographic	 control	 [1-3];	which	 has	 been	
reported	to	restore	valve	function	in	the	majority	
of	these	cases	[10].	None	of	our	cases	fitted	those	
criteria,	 being	 a	 tertiary	 center	 most	 of	 our	
patients	are	usually	referred	after	a	considerable	
time	delay	from	the	onset	of	alarming	symptoms	
or	even	the	confirmation	of	diagnosis	 in	another	
hospital;	with	all	patients	being	admitted	in	NYHA	
class	 III	 or	 IV.	 Major	 American	 and	 European	
societies	agree	on	 the	primary	 role	of	 surgery	 in	
those	critically	 ill	patients	with	 left-sided	PVT	 [1-
3],	 with	 few	 detailed	 differences.	 American	
societies	 recommend	 surgery	 for	 all	 patients	
presenting	with	NYHA	class	III	to	IV	symptoms	[3],	
as	well	as	for	those	case	with	a	mobile	[3]	or	large	
thrombus	 >0.8	 cm2	 on	 TEE	 [2,	 3].	 European	
societies	 recommend	 surgery	 to	 critically	 ill	
patients,	 when	 the	 thrombus	 is	 shown	 to	 be	
obstructive	 on	 TEE	 or	 >10	 mm	 in	 diameter	 and	
embolising	 [1].	 All	 our	 patients	 fitted	 in	 one	 of	
those	 criteria.	 Due	 to	 the	 high	 risk	 of	 maternal	
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and	fetal	complications	after	surgery,	the	society	
of	 heart	 valve	 disease	 recommends	 fibrinolytic	
therapy	 (FT)	 to	 all	 patients	 with	 left-sided	 PVT,	
limiting	 the	 role	 of	 surgery	 to	 cases	where	 FT	 is	
contraindicated	[9].	
In	 the	actual	 era,	maternal	 outcomes	are	
comparable	 to	 those	 of	 non-pregnant	 subjects	
undergoing	 bypass	 for	 similar	 diseases	 [11-14].	
Two	recent	systematic	reviews	involving	690	[15]	
and	 2302	 cases	 presenting	 with	 PVT	 [16]	 have	
shown	 that	 surgery	 was	 associated	 with	 better	
complete	 restoration	 of	 valve	 function	 (82-87%	
versus	 70-81%),	 reduction	 in	 thromboembolic	
events	 (1.6-8.9%	 versus	 11-16%)	 bleeding	
episodes	(1.4-4.6%	versus	5-6.8%)	and	recurrence	
of	 PVT	 (7.1%	 versus	 25.4%)	 but	 higher	mortality	
(13.5-18%	 versus	 6.6-9%),	 compared	 to	 FT	 [15,	
16].	Our	7.1%	mortality	and	3.6%	stroke	rates	are	
quite	matching	with	those	calculations	as	well	as	
with	higher	mortality	rates	(8.7%-13.3%)	reported	
for	 critically	 ill	 pregnant	 patients	 undergoing	
cardiopulmonary	 bypass	 for	 different	 cardiac	
pathology	[12,	17]	
In	contradiction,	fetal	outcome	raises	a	lot	
of	 concerns.	 There	 is	 a	 general	 agreement	 that	
hypothermia	has	a	deleterious	effect	on	the	fetus	
[11-14,	 17-21].	 The	 institution	 of	 CPB	 activates	
eicosanoid	 products,	 which	 increase	 placental	
vascular	resistance	and	lead	to	malperfusion	[21].	
Uterine	 excitability	 is	 also	 increased	 during	
bypass,	 most	 probably	 for	 progesterone	 being	
diluted	 [18]	 The	 additional	 use	 of	 hypothermia	
further	 reduces	 O2	 exchange	 through	 the	
placenta,	aggravating	placental	malperfusion	and	
provoking	 more	 contractions	 of	 an	 already	
excitable	 uterus	 [18].	 The	 end	 result	 is	 fetal	
hypoxia	 manifesting	 by	 fetal	 bradycardia	 that	
appears	 at	 the	 beginning	 of	 bypass	 and	 usually	
ends	by	its	termination	[22].	In	one	study,	the	use	
of	 hypothermia	 was	 associated	 with	 24%	 fetal	
mortality,	compared	to	none	in	patients	operated	
under	 normothermic	 bypass	 [19].	 This	 process	
has	turned	out	to	be	reversible	by	increasing	the	
perfusion	 [23].	Experimental	 studies	have	shown	
that	both	hypothermia	at	 any	 flow	 rate	and	 low	
flow	rate	at	normothermia	were	associated	with	
significant	 hypoxia,	 compared	 to	 normal	 flow	
under	 normothermia	 [21].	 Our	 measures	 to	
improve	 fetal	 condition	 during	 bypass	 included:	
maintaining	uterine	displacement	to	avoid	aorto-
caval	compression,	the	use	of	normothermic	high	
flow	 bypass	 (>2.7L/m2/min),	 maintaining	 mean	
arterial	 pressure	 >70	 mm	 Hg	 and	 minimizing	
bypass	 time,	 intraoperative	 blood	 loss	 and	
maintaining	 hematocrit	 >28%.	 	We	 have	missed	
the	benefits	of	pulsatile	flow	and	fetal	monitoring	
during	 and	 early	 after	 bypass.	 Pulsatile	 flow	 is	
thought	 to	 improve	 placenta	 perfusion	 by	
decreasing	 both:	 uterine	 contraction	 through	
enhancing	 the	 release	 of	 endothelium–derived	
growth	factor	from	the	vascular	endothelium	[24]	
and	 placental	 vascular	 resistance	 through	
reducing	the	activation	of	fetal	renin-angiotensin-
aldosterone	 axis	 [25].	 Monitoring	 uterine	
contraction	 and	 fetal	 heart	 rate	 during	 bypass	
allow	adjustments	to	the	flow	and	pharmacologic	
manipulations	 to	 ensure	 adequate	 placental	
perfusion	[11,	13,	14,	19,	20].		
Fetal	 mortality	 after	 cardiopulmonary	
bypass	 shows	 a	 wide	 variation	 form	 14%	 to	 as	
much	 as	 41%	 [11-14,	 17,	 19],	 reflecting	 the	
limited	size	of	reported	series	as	well	as	the	large	
spectrum	of	patients	with	variable	seriousness	of	
illness	 and	 associated	 comorbidities.	 The	 lowest	
mortality	was	presented	in	a	series	of	21	patients:	
50%	 were	 elective	 cases	 and	 only	 one	 patient	
presented	 with	 PVTP	 [14].	 Surgery	 was	 quite	
quick	 with	 a	 short	 median	 bypass	 time	 of	 53	
minutes	[14].	The	highest	mortality	figures	(38,5%	
and	 41%)	 were	 presented	 in	 2	 series	 of	 15	 [12]	
and	 23	 patients	 [17].	 In	 one	 study,	 74%	 of	 the	
cases	had	a	stuck	mitral	valve	[17].	Eighty	percent	
of	the	patients	in	both	studies	were	in	NYHA	class	
III-IV	and	surgery	appeared	to	be	time	consuming	
for	 necessitating	 relatively	 long	 bypass	 (median	
95	 and	 mean	 89	 minutes)	 [12,	 17].	 Our	
corresponding	 27.3%	 fetal	 mortality	 reflects	 the	
seriousness	 of	maternal	 condition	 however,	 one	
has	 to	 acknowledge	 the	 deleterious	 effect	 of	
cardiopulmonary	 bypass.	 No	 fetal	 mortality	 was	
recorded	among	Group	1	patients,	where	93%	of	
the	 fetuses	 escaped	 bypass	 by	 being	 delivered	
before	 surgery;	 which	 is	 considered	 to	 be	 the	
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best	available	option	in	PVTP	[11,	14,	17].	On	the	
other	hand,	fetal	mortality	was	as	much	as	66.6%	
among	 the	 nine	 cases	 subjected	 to	 bypass,	 all	
belonging	 to	 Group	 2	 patients;	 confirming	 the	
fact	 that	 the	 heavy	 costs	 of	 bypass	 are	 usually	
paid	by	the	younger	fetuses	[11,	14;	17].		
In	 order	 to	 avoid	 the	 serious	 fetal	 and	
maternal	 complications	 associated	 with	 surgery,	
FT	has	been	 suggested	as	 first	 line	management	
in	 all	 patients	 presenting	 with	 PVTP	 [8-10].	 A	
recent	 literature	 review	 involving	 38	 cases	
reported	 over	 three	 decades	 has	 shown:	 76%	
thrombolytic	 success,	 10%	 maternal	 mortality,	
14%	major	 complication	 and	28%	 fetal	mortality	
[8].	Ozkan	and	colleagues	have	recently	reported	
the	 use	 of	 TEE-guided	 slow	 infusion	 of	 a	 small	
dose	 of	 tissue	 type	 plasminogen	 activator	 (t-PA)	
in	a	series	of	25	PVTP;	regardless	of	the	thrombus	
being	 obstructive	 or	 not	 and	 irrespective	 to	 the	
patient’s	NYHA	 class	 [8].	 There	was	no	maternal	
mortality	 but	 three	 cases	 of	 recurrence	 during	
the	 same	 pregnancy	 (12%)	 and	 five	 fetal	
mortalities	 (20%).	 Like	 in	 our	 series,	 fetal	
mortalities	 were	 exclusively	 recorded	 among	
patients	 presenting	 with	 young	 GA	 <28	 weeks,	
resulting	 in	 as	 much	 as	 29.4%	 fetal	 loss	 among	
the	latter	group	[8],	which	is	still	much	lower	than	
our	 corresponding	 rate.	 Surprisingly,	 Ozkan	 and	
colleagues	recorded	a	single	mortality	among	the	
“high-risk	 group”	 of	 13	 patients	 presenting	with	
NYHA	 class	 III-IV	 and	 obstructive	 thrombus	 on	
TEE,	compared	to	as	much	as	4	mortalities	among	
the	 “low-risk	 group”	 of	 12	 patients	 presenting	
with	NYHA	class	I-II	and	mostly	(92%)	having	non-
obstructive	thrombus	on	TEE.	 In	other	words,	FT	
achieved	good	 fetal	outcome	 (7.7%	mortality)	 in	
surgical	 candidates	 but	 the	worst	 results	 (33.3%	
mortality)	 in	 candidates	 for	 FT;	 being	 defined	 as	
such	according	to	the	current	guidelines	[1-3].	 In	
consequence,	and	despite	that	the	use	of	FT	was	
associated	 with	 considerable	 60%	 reduction	 of	
fetal	 mortality	 among	 the	 subgroup	 of	 patients	
presenting	 with	 gestational	 age	 <28	 weeks,	 the	
neutralization	 of	 the	 effect	 of	 maternal	
hemodynamic	 deterioration	 and	 serious	 TEE	
findings	needs	to	be	investigated.	
Conclusion:	Prosthetic	valve	thrombosis	during	
pregnancy	 was	 mainly	 noted	 in	 patients	 with	
unmonitored	and/or	unadjusted	anticoagulation,	
especially	 those	 receiving	 LMWH.	 Maternal	
mortality	is	comparable	to	those	recorded	in	non-
pregnant	patients.	Unless	delivery	can	be	carried	
out	 before	 surgery,	 fetal	 loss	 is	 majored	 after	
cardiopulmonary	 bypass,	 especially	 among	
younger	 gestation	 age	 and	 hence,	 more	
protective	 measures	 should	 be	 investigated.	
There	is	not	enough	evidence	in	the	literature	to	
recommend	alternative	FT	for	this	group	of	high-
risk	 patients	 and	 randomized	 clinical	 trials	 are	
needed	 to	 validate	 the	 best	 option	 according	 to	
the	 patient’s	 clinical	 and	 echocardiographic	
finding	and	the	fetal	gestational	age.		
Study	 limitations:	Eleven	of	our	cases	(39.3%)	
were	 previously	 reported	 among	 a	 series	 of	 23	
pregnant	patients	undergoing	emergency	surgery	
for	 different	 valve	 pathology	 [17].	 The	 previous	
report	did	not	show	relevant	information	for	each	
patient	 namely;	 NYHA	 class,	 duration	 of	 valve	
implantation	 and	 type	 of	 anticoagulation	
regimen.	 The	 high	 post	 bypass	 fetal	 mortality	
among	 patients	 presenting	 with	 GA	 <28	 weeks	
may	 have	 been	 improved	 if	we	managed	 to	 use	
pulsatile	 flow	 and	 applied	 effective	 fetal	
monitoring	during	and	early	after	bypass.	Being	a	
tertiary	 referral	 site,	 long-term	 clinical	 follow-up	
was	not	available	for	many	patients.		
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